Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 349

1.

Lack of immunohistochemical detection of VEGF in prostate carcinoma.

Kamath A, Helie M, Bifulco CB, Li WW, Concato J, Jain D.

Appl Immunohistochem Mol Morphol. 2009 May;17(3):227-32. doi: 10.1097/PAI.0b013e31818f9e7f.

PMID:
19098681
2.

Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.

Safwat MD, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S.

Folia Morphol (Warsz). 2009 Aug;68(3):144-55.

PMID:
19722158
3.

Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues.

Wu TT, Wang JS, Jiann BP, Yu CC, Tsai JY, Lin JT, Huang JK.

J Chin Med Assoc. 2007 Sep;70(9):380-4.

4.

Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.

Tang J, Wang Z, Li X, Li J, Shi H.

Artif Cells Blood Substit Immobil Biotechnol. 2008;36(2):83-93. doi: 10.1080/10731190801932074.

PMID:
18437586
5.

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.

Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, Kosicek M, Cacic M.

Prostate. 2006 Jan 1;66(1):13-8.

PMID:
16114059
7.

False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.

Ali TZ, Epstein JI.

Am J Surg Pathol. 2008 Dec;32(12):1890-5. doi: 10.1097/PAS.0b013e31817ce994.

PMID:
18813120
8.

P504S: a new molecular marker for the detection of prostate carcinoma.

Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR.

Am J Surg Pathol. 2001 Nov;25(11):1397-404.

PMID:
11684956
9.

Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.

El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS.

Am J Clin Pathol. 2007 Apr;127(4):572-9.

PMID:
17369132
10.

[Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance].

Jin TX, Li XG, Wu WY, Piao DM, Feng JY, Sang J.

Zhonghua Nan Ke Xue. 2006 Mar;12(3):207-10. Chinese.

PMID:
16597032
11.

Mesonephric remnants of the prostate: incidence and histologic spectrum.

Bostwick DG, Qian J, Ma J, Muir TE.

Mod Pathol. 2003 Jul;16(7):630-5.

12.

[Expression of kinase insert domain-containing receptor in prostate adenocarcinoma].

Bai AS, Zeng H, Li X, Wei Q, Li H, Yang YR.

Zhonghua Nan Ke Xue. 2007 Apr;13(4):324-6. Chinese.

PMID:
17491265
13.

Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study.

Giri DK, Wadhwa SN, Upadhaya SN, Talwar GP.

Prostate. 1993;23(4):329-36.

PMID:
7505056
15.

Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma.

Googe PB, McGinley KM, Fitzgibbon JF.

Am J Clin Pathol. 1997 Feb;107(2):219-23.

PMID:
9024071
16.

Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.

Lane Z, Hansel DE, Epstein JI.

Am J Surg Pathol. 2008 Sep;32(9):1322-6. doi: 10.1097/PAS.0b013e3181656ca0.

PMID:
18670358
17.

Expression and immunolocalisation of neutral endopeptidase in prostate cancer.

Albrecht M, Mittler A, Wilhelm B, Lundwall A, Lilja H, Aumüller G, Bjartell A.

Eur Urol. 2003 Oct;44(4):415-22.

PMID:
14499674
19.

The expression of vascular endothelial growth factor and its receptors in port-wine stains.

Vural E, Ramakrishnan J, Cetin N, Buckmiller L, Suen JY, Fan CY.

Otolaryngol Head Neck Surg. 2008 Oct;139(4):560-4. doi: 10.1016/j.otohns.2008.07.015.

PMID:
18922344
20.

Supplemental Content

Support Center